Kent Meningitis Outbreak: Why Students Missed a Key Vaccine & What Happens Next

A recent outbreak of meningitis at the University of Kent has tragically resulted in two deaths and left 20 students receiving treatment, highlighting a critical gap in UK vaccination policy. The affected students, part of a generation born before routine vaccination programs were adjusted, were never routinely immunized against the specific strain – meningococcal group B – responsible for this outbreak. This situation underscores a complex interplay between vaccine efficacy, economic considerations, and public health protection.

The Bexsero Vaccine and the 2015 Policy Shift

The vaccine to prevent this particular strain, Bexsero, has been available since 2013. In September 2015, the UK became the first country globally to incorporate Bexsero into its national immunization schedule, but with a significant limitation: the program was exclusively offered to infants. As reported by The Conversation, every student currently enrolled in university was born before July 2015, effectively excluding them from receiving the jab through the National Health Service. No subsequent catch-up program was ever implemented, leaving an entire decade of university students vulnerable to this common form of bacterial meningitis.

This decision wasn’t made lightly. The Joint Committee on Vaccination and Immunisation (JCVI), the UK government’s advisory body on vaccines, determined that the benefits of extending the program beyond infants did not meet the economic threshold required to justify the cost. Unlike some vaccines that offer “herd immunity” – protecting even those unvaccinated when a large portion of the population is immunized – Bexsero only protects the individual who receives it. It doesn’t reduce the amount of bacteria carried in the throat, meaning it doesn’t prevent wider circulation of the disease.

University Life: A High-Risk Environment

The JCVI’s assessment, however, may not have fully accounted for the unique risks associated with university life. Meningococcal bacteria spread through close contact – kissing, sharing drinks, coughing in crowded spaces. Universities, with their halls of residence, social events, and bustling campus environments, provide ideal conditions for transmission. Research dating back decades has established a link between university life and increased meningococcal risk.

Studies demonstrate this elevated risk. One study tracking students during their first week at a UK university found that the proportion carrying the bacteria in their throats jumped from less than 7% to over 23% within just four days, reaching 34% in catered halls by December. Similarly, US research indicates that first-year undergraduate students face a risk of meningococcal B disease nearly 12 times higher than their non-student peers of the same age, with the risk further amplified by living in halls of residence.

The Cost of Protection and Access Inequality

For parents who wished to protect their children privately, the Bexsero vaccine was available, but at a cost. A full course requires two doses for anyone over 11, with each dose costing around £110 at most UK pharmacies, totaling £220 or more. Some private clinics charge even higher fees. This creates a disparity in access, where protection is dependent on financial means. Following the Kent outbreak, bookings for private meningitis B vaccinations at Superdrug surged 65 times their normal level, demonstrating a clear demand driven by those who can afford it.

Re-evaluating the Economic Calculus

The economic justification for limiting the vaccination program to infants is now being re-examined. A re-analysis published in 2021 in the journal Value in Health suggests that when considering the broader impact of the disease – including long-term care, lost earnings, and the effects on families – the cost per year of healthy life gained falls below the NHS’s standard threshold for approving treatments. The initial cost savings from not vaccinating teenagers may be offset by long-term costs that were not initially factored into the equation.

the outbreak itself incurs significant costs. More than 30,000 people in the Canterbury area have been contacted by health authorities, and thousands of doses of antibiotics have been distributed. A targeted vaccination campaign has been launched for students in halls of residence, adding to the financial burden.

What Comes Next: A Policy Review and Ongoing Surveillance

Health Secretary Wes Streeting has announced that he will ask the JCVI to re-examine eligibility for meningitis vaccines in light of the outbreak. This review is a welcome, and overdue, step. The first cohort of babies vaccinated in 2015 will not reach university age until 2033, meaning that current university students will continue to be at risk unless policy changes are made.

Beyond the policy review, ongoing surveillance is crucial. Public health teams will continue to monitor the situation closely, identifying and contacting close contacts of those affected. The UK Health Security Agency (UKHSA) is arranging antibiotics for students in the Canterbury area and working to identify the specific strain of meningitis involved in the outbreak. This information will be vital for informing future vaccination strategies and public health interventions. It’s important to remember that meningitis can be serious if not treated promptly, and anyone experiencing symptoms should seek urgent medical attention.

The tragic events at the University of Kent serve as a stark reminder of the complex challenges involved in vaccine policy and the importance of continually re-evaluating the balance between economic considerations and public health protection.